Loading...

We've got a brand new version of Simply Wall St! Try it out

PreveCeutical Medical

CNSX:PREV
Snowflake Description

Weak fundamentals or lack of information.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
PREV
CNSX
CA$12M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

PreveCeutical Medical Inc., a health sciences company, develops options for preventive and curative therapies utilizing organic and nature identical products in the United States and Canada. The last earnings update was 27 days ago. More info.


Add to Portfolio Compare Print
  • PreveCeutical Medical has significant price volatility in the past 3 months.
PREV Share Price and Events
7 Day Returns
0%
CNSX:PREV
-5.9%
CA Pharmaceuticals
1.3%
CA Market
1 Year Returns
-62.5%
CNSX:PREV
-46.7%
CA Pharmaceuticals
-0.1%
CA Market
PREV Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
PreveCeutical Medical (PREV) 0% -25% -33.3% -62.5% - -
CA Pharmaceuticals -5.9% -3.4% -24.8% -46.7% 217.3% 286.4%
CA Market 1.3% 4.2% 1.6% -0.1% 8.4% 5.7%
1 Year Return vs Industry and Market
  • PREV underperformed the Pharmaceuticals industry which returned -46.7% over the past year.
  • PREV underperformed the Market in Canada which returned -0.1% over the past year.
Price Volatility
PREV
Industry
5yr Volatility vs Market

Value

 Is PreveCeutical Medical undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether PreveCeutical Medical is trading at an attractive price based on the cash flow it is expected to produce in the future. But as PreveCeutical Medical has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for PreveCeutical Medical. This is due to cash flow or dividend data being unavailable. The share price is CA$0.03.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for PreveCeutical Medical's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are PreveCeutical Medical's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:PREV PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in CAD CA$-0.03
CNSX:PREV Share Price ** CNSX (2019-09-20) in CAD CA$0.03
Canada Pharmaceuticals Industry PE Ratio Median Figure of 13 Publicly-Listed Pharmaceuticals Companies 15.3x
Canada Market PE Ratio Median Figure of 539 Publicly-Listed Companies 14.14x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of PreveCeutical Medical.

CNSX:PREV PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:PREV Share Price ÷ EPS (both in CAD)

= 0.03 ÷ -0.03

-1.05x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • PreveCeutical Medical is loss making, we can't compare its value to the CA Pharmaceuticals industry average.
  • PreveCeutical Medical is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does PreveCeutical Medical's expected growth come at a high price?
Raw Data
CNSX:PREV PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.05x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Canada Pharmaceuticals Industry PEG Ratio Median Figure of 7 Publicly-Listed Pharmaceuticals Companies 1.56x
Canada Market PEG Ratio Median Figure of 245 Publicly-Listed Companies 1.02x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for PreveCeutical Medical, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on PreveCeutical Medical's assets?
Raw Data
CNSX:PREV PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in CAD CA$-0.01
CNSX:PREV Share Price * CNSX (2019-09-20) in CAD CA$0.03
Canada Pharmaceuticals Industry PB Ratio Median Figure of 151 Publicly-Listed Pharmaceuticals Companies 2.36x
Canada Market PB Ratio Median Figure of 2,457 Publicly-Listed Companies 1.43x
CNSX:PREV PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:PREV Share Price ÷ Book Value per Share (both in CAD)

= 0.03 ÷ -0.01

-2.72x

* Primary Listing of PreveCeutical Medical.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • PreveCeutical Medical has negative assets, we can't compare the value of its assets to the CA Pharmaceuticals industry average.

Next steps:

  1. Take a look at our analysis of PREV’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through PreveCeutical Medical's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Pharmaceuticals industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess PreveCeutical Medical's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. PreveCeutical Medical has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is PreveCeutical Medical expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as PreveCeutical Medical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
97.7%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is PreveCeutical Medical expected to grow at an attractive rate?
  • Unable to compare PreveCeutical Medical's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare PreveCeutical Medical's earnings growth to the Canada market average as no estimate data is available.
  • Unable to compare PreveCeutical Medical's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
CNSX:PREV Future Growth Rates Data Sources
Data Point Source Value (per year)
Canada Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 97.7%
Canada Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 56.5%
Canada Market Earnings Growth Rate Market Cap Weighted Average 12.6%
Canada Market Revenue Growth Rate Market Cap Weighted Average 5.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:PREV Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:PREV Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-06-30 0 -4 -11
2019-03-31 0 -7 -12
2018-12-31 0 -8 -12
2018-09-30 0 -8 -9
2018-06-30 0 -8 -7
2018-03-31 0 -5 -8
2017-12-31 0 -4 -7
2017-09-30 0 -3 -6
2017-06-30 0 -2 -6
2017-03-31 0 -2 -3
2016-12-31 0 -1 -3

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if PreveCeutical Medical is high growth as no earnings estimate data is available.
  • Unable to determine if PreveCeutical Medical is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:PREV Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from PreveCeutical Medical Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:PREV Past Financials Data
Date (Data in CAD Millions) EPS *
2019-06-30 -0.03
2019-03-31 -0.03
2018-12-31 -0.04
2018-09-30 -0.03
2018-06-30 -0.03
2018-03-31 -0.04
2017-12-31 -0.03
2017-09-30 -0.03
2017-06-30 -0.03
2017-03-31 -0.02
2016-12-31 -0.02

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if PreveCeutical Medical will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of PREV’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. PreveCeutical Medical's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. PreveCeutical Medical's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess PreveCeutical Medical's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
PreveCeutical Medical has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has PreveCeutical Medical performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare PreveCeutical Medical's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • PreveCeutical Medical does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare PreveCeutical Medical's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare PreveCeutical Medical's 1-year growth to the CA Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
PreveCeutical Medical's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from PreveCeutical Medical Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:PREV Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 0.00 -11.22 3.10 2.69
2019-03-31 0.02 -11.64 3.84 2.68
2018-12-31 0.02 -11.88 4.48 2.36
2018-09-30 0.00 -8.87 5.83 2.30
2018-06-30 0.01 -7.34 5.07 1.67
2018-03-31 0.02 -8.28 4.46 0.90
2017-12-31 0.02 -7.23 3.87 0.52
2017-09-30 0.04 -6.48 3.40 0.20
2017-06-30 0.04 -5.91 3.00 0.02
2017-03-31 0.03 -3.31 2.83 0.00
2016-12-31 0.03 -3.13 2.67
2015-12-31 -0.49 0.49

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if PreveCeutical Medical has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if PreveCeutical Medical has efficiently used its assets last year compared to the CA Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if PreveCeutical Medical improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.
X
Past performance checks
We assess PreveCeutical Medical's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
PreveCeutical Medical has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is PreveCeutical Medical's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up PreveCeutical Medical's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • PreveCeutical Medical's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • PreveCeutical Medical's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of PreveCeutical Medical's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • PreveCeutical Medical has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from PreveCeutical Medical Company Filings, last reported 2 months ago.

CNSX:PREV Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 -4.38 4.37 0.04
2019-03-31 -3.06 4.02 0.06
2018-12-31 -2.29 3.65 0.06
2018-09-30 0.97 3.36 0.86
2018-06-30 3.29 3.79 2.86
2018-03-31 -1.41 3.65 0.20
2017-12-31 -0.34 2.73 0.10
2017-09-30 -0.53 2.44 0.49
2017-06-30 0.65 2.41 2.29
2017-03-31 -0.51 0.81 0.15
2016-12-31 -0.30 0.13
2015-12-31 0.04 0.02
  • PreveCeutical Medical has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if PreveCeutical Medical's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • PreveCeutical Medical has less than a year of cash runway based on current free cash flow.
  • PreveCeutical Medical has less than a year of cash runway if free cash flow continues to grow at historical rates of 39.7% each year.
X
Financial health checks
We assess PreveCeutical Medical's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. PreveCeutical Medical has a total score of 0/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is PreveCeutical Medical's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from PreveCeutical Medical dividends.
If you bought CA$2,000 of PreveCeutical Medical shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate PreveCeutical Medical's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate PreveCeutical Medical's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:PREV Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
North America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.8%
Canada Market Average Dividend Yield Market Cap Weighted Average of 334 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.1%
Canada Bottom 25% Dividend Yield 25th Percentile 2%
Canada Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as PreveCeutical Medical has not reported any payouts.
  • Unable to verify if PreveCeutical Medical's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of PreveCeutical Medical's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as PreveCeutical Medical has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess PreveCeutical Medical's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can PreveCeutical Medical afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. PreveCeutical Medical has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of PreveCeutical Medical's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Stephen Van Deventer
COMPENSATION CA$172,935
AGE 50
TENURE AS CEO 2.3 years
CEO Bio

Mr. Stephen Van Deventer serves as the Chairman at Preveceutical Medical Inc. and has been its Chief Executive Officer since June 22, 2017. Mr. Van Deventer was the President of Preveceutical Medical Inc. since April 9, 2018 until February 13, 2019. He is an Entrepreneur and Owner of Cornerstone Global Partners Inc. He is an experienced businessman, corporate Director and co-owner of Cornerstone Global Partners Inc. Specializing in international corporate relations and business development over the last 25 years. He is a Founder of the Preveceutical Medical Inc. He has been Director at Carrara Exploration Corp since May 19, 2017. Mr. Van Deventer has focused on launching small to medium sized companies into the public markets in Canada, the United States and Europe. He has also owned and operated private companies. He has been a Director of Preveceutical Medical Inc. since May 19, 2017.

CEO Compensation
  • Stephen's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Stephen's remuneration is about average for companies of similar size in Canada.
Management Team Tenure

Average tenure and age of the PreveCeutical Medical management team in years:

2.2
Average Tenure
50
Average Age
  • The tenure for the PreveCeutical Medical management team is about average.
Management Team

Stephen Van Deventer

TITLE
COMPENSATION
CA$173K
AGE
50
TENURE
2.3 yrs

Mak Jawadekar

TITLE
Chief Science Officer
COMPENSATION
CA$321K
AGE
68
TENURE
0.6 yrs

Shabira Rajan

TITLE
CFO & Controller
COMPENSATION
CA$153K
AGE
63
TENURE
2.3 yrs

Deanna Kress

TITLE
Director of Corporate Communications & Investor Relations
TENURE
2.2 yrs

Alicia Rebman

TITLE
Marketing Director
AGE
42
TENURE
1.8 yrs

Harry Parekh

TITLE
Chief Research Officer
TENURE
2.3 yrs

Nicole Goncalves-Krysinski

TITLE
Foreign Legal Advisor
AGE
40
TENURE
1.8 yrs
Board of Directors Tenure

Average tenure and age of the PreveCeutical Medical board of directors in years:

0.6
Average Tenure
66
Average Age
  • The average tenure for the PreveCeutical Medical board of directors is less than 3 years, this suggests a new board.
Board of Directors

Stephen Van Deventer

TITLE
COMPENSATION
CA$173K
AGE
50

Mak Jawadekar

TITLE
Chief Science Officer
COMPENSATION
CA$321K
AGE
68
TENURE
1.9 yrs

Keith Anderson

TITLE
Independent Director
TENURE
0.3 yrs

Mark Lotz

TITLE
Independent Director
TENURE
0.3 yrs

Isaac Moss

TITLE
Member of Advisory Board
AGE
66

Ruth Henderson

TITLE
Member of Advisory Board

Ian Spencer

TITLE
Member of Advisory Board

Wanda Halpert

TITLE
Member of Advisory Board

Paget Hargreaves

TITLE
Director of PreveCeutical (Australia) Pty Ltd.
COMPENSATION
CA$212K
TENURE
0.9 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
X
Management checks
We assess PreveCeutical Medical's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. PreveCeutical Medical has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

The PreveCeutical Medical (CNSX:PREV) Share Price Is Down 13% So Some Shareholders Are Getting Worried

View our latest analysis for PreveCeutical Medical We don't think PreveCeutical Medical's revenue of CA$4,856 is enough to establish significant demand. … Investors will be hoping that PreveCeutical Medical can make progress and gain better traction for the business, before it runs low on cash. … You could get a better understanding of PreveCeutical Medical's growth by checking out this more detailed historical graph of earnings, revenue and cash flow.

Simply Wall St -

Have Insiders Been Buying PreveCeutical Medical Inc. (CNSX:PREV) Shares?

But logic dictates you should pay some attention to whether insiders are buying or selling shares. … The Last 12 Months Of Insider Transactions At PreveCeutical Medical … While there weren't any large insider transactions in the last twelve months, it's still worth looking at the trading

Simply Wall St -

Can We See Significant Insider Ownership On The PreveCeutical Medical Inc (CNSX:PREV) Share Register?

The big shareholder groups in PreveCeutical Medical Inc (CNSX:PREV) have power over the company. … Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. … PreveCeutical Medical is a smaller company with a market capitalization of CA$37m, so it may still be flying under the radar of many institutional investors.

Simply Wall St -

Who Are The Major Shareholders In PreveCeutical Medical Inc (CNSX:PREV)?

Today, I will be analyzing PreveCeutical Medical Inc’s (CNSX:PREV) recent ownership structure, an important but not-so-popular subject among individual investors. … When it comes to ownership structure of a company, the impact has been observed in both the long-and short-term performance of shares. … Therefore, it is beneficial for us to examine PREV's ownership structure in more detail.

Simply Wall St -

Company Info

Description

PreveCeutical Medical Inc., a health sciences company, develops options for preventive and curative therapies utilizing organic and nature identical products in the United States and Canada. It has research and development programs, including dual gene therapy for curative and prevention therapies for type 2 diabetes and obesity; a soluble gel drug delivery program; Nature Identical peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the addictive analgesics, such as morphine, fentanyl, and oxycodone; and a therapeutic product for treating athletes who suffer from concussions. It also provides medicinal cannabis-based products. The company has research partnerships with University of Queensland; and the UniQuest Pty Limited for the development and evaluation of translatable formulations for systemic/central nervous system delivery. PreveCeutical Medical Inc. is headquartered in Vancouver, Canada.

Details
Name: PreveCeutical Medical Inc.
PREV
Exchange: CNSX
Founded:
CA$11,893,467
396,448,905
Website: http://www.preveceutical.com
Address: PreveCeutical Medical Inc.
1177 West Hastings Street,
Suite 2200,
Vancouver,
British Columbia, V6E 2K3,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX PREV New Common Shares Canadian National Stock Exchange CA CAD 04. Jul 2017
OTCPK PRVC.F New Common Shares Pink Sheets LLC US USD 04. Jul 2017
DB 18H New Common Shares Deutsche Boerse AG DE EUR 04. Jul 2017
Number of employees
Current staff
Staff numbers
0
PreveCeutical Medical employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/09/22 00:48
End of day share price update: 2019/09/20 00:00
Last earnings filing: 2019/08/26
Last earnings reported: 2019/06/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.